SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-237644
Filing Date
2023-09-19
Accepted
2023-09-19 16:16:53
Documents
14
Period of Report
2023-09-19
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d541406d8k.htm   iXBRL 8-K 35598
2 EX-3.1 d541406dex31.htm EX-3.1 33353
3 EX-3.2 d541406dex32.htm EX-3.2 189753
  Complete submission text file 0001193125-23-237644.txt   438391

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA nmra-20230919.xsd EX-101.SCH 2878
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE nmra-20230919_lab.xml EX-101.LAB 19483
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nmra-20230919_pre.xml EX-101.PRE 12172
8 EXTRACTED XBRL INSTANCE DOCUMENT d541406d8k_htm.xml XML 3677
Mailing Address 490 ARSENAL WAY, SUITE 200 WATERTOWN MA 02472
Business Address 490 ARSENAL WAY, SUITE 200 WATERTOWN MA 02472 (857) 760-0900
Neumora Therapeutics, Inc. (Filer) CIK: 0001885522 (see all company filings)

IRS No.: 844367680 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41802 | Film No.: 231263999
SIC: 2836 Biological Products, (No Diagnostic Substances)